Testing the Reliability and Validity of Pupil Diameter in Opioid-exposed neonates

测试阿片类药物暴露新生儿瞳孔直径的可靠性和有效性

基本信息

  • 批准号:
    8293516
  • 负责人:
  • 金额:
    $ 41.81万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-09-15 至 2015-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Pupil diameter is one of the most frequently assessed objective indices of the pharmacodynamic effects of opioids in humans. The pupillary effects of opioids are easily measured photographically in adults and are a highly sensitive measure of the presence and extent of physical dependence and withdrawal. Measures of pupillary response are often collected along with self-reported and observer-rated effects to provide a comprehensive profile of opioid effects. Infants exposed to opioids in utero are born physically dependent and often suffer from withdrawal (i.e., neonatal abstinence syndrome~ NAS) that is severe enough to require pharmacological treatment. Observer- rated scales are the only tools available to evaluate the need for and effectiveness of pharmacological treatment for NAS in both clinical and research settings and shortcomings of these instruments (e.g., rudimentary validation, long training and administration times) have led to calls for more sensitive, objective measures of NAS. We have developed a protocol to measure pupil diameter in opioid-exposed neonates. Pilot data (N=10) using this protocol indicate neonatal pupils respond to opioids in the same manner as adults and suggest that pupil diameter may be a more sensitive measure of NAS compared to observer-rated scales. Thus, the next step is to fully test the reliability and validity of pupil diameter in opioid-exposed neonates. Two studies are proposed to meet this overarching aim. The first study will formally test the reliability of ou pupil photography protocol in 40 opioid-exposed neonates. The second study will test the validity of pupillary changes in neonates as an index of opioid effects using the extensive adult literature on the pupillary effects of opioids as a guide. One-hundred ten opioid-exposed neonates and 30 non-exposed neonates will provide data for four analyses of validity. First, pupil diameter measurements collected over the first 24 hours after delivery will be examined to see if they discriminate between opioid-exposed and non-exposed neonates, testing discriminant validity. Second, among the opioid-exposed neonates, correlations between changes in pupil diameter and changes in observer-rated NAS scale scores over the first 24 hours after delivery will be examined, testing concurrent validity. Third, opioid tolerance and the time course of pupillary effects after opioid administration will be examined among the opioid-exposed neonates who require pharmacological treatment (estimated n= 35), testing construct validity. The fourth and final analysis will examine predictive validity by testing whether changes in pupil diameter in the first 24 hours after delivery predicts which neonates went on to receive pharmacological treatment. In sum, establishing the reliability and validit of pupil diameter in opioid-exposed neonates has potential to substantially improve assessment and treatment of opioid-exposed neonates in both clinical and research settings, reducing morbidity, shortening hospital stays, and decreasing costs. PUBLIC HEALTH RELEVANCE: Pupil size is one of the most sensitive and commonly used measures of the severity of withdrawal from opiate drugs (like heroin and methadone) as well as other effects of opiate drugs and is easily measured in pictures taken of adult eyes. To our knowledge, pupil size has never been measured in infants withdrawing from opiate drugs after exposure in utero. The primary aim of the proposed studies is to test the reliability and validity f pupil size measured photographically in opiate-exposed infants. The proposed research has significant potential for improving the detection and treatment of withdrawal signs in this special population.
描述(由申请方提供):瞳孔直径是阿片类药物在人体中药效学作用最常评估的客观指标之一。阿片类药物的瞳孔效应很容易在成人中进行测量,并且是身体依赖和戒断的存在和程度的高度敏感的测量。瞳孔反应的测量值通常与自我报告和自我评价的效应一起收集沿着,以提供阿片类药物效应的综合特征。在子宫内暴露于阿片类药物的婴儿出生时身体依赖,并且经常患有戒断(即,新生儿戒断综合征(NAS),严重到需要药物治疗。观察员评定量表是唯一可用于评价药物治疗的必要性和有效性的工具 对于临床和研究环境中的NAS以及这些仪器的缺点(例如, 基本的验证、长的培训和管理时间)已经导致对NAS的更敏感、客观的测量的要求。 我们已经制定了一个协议来测量瞳孔直径阿片类药物暴露的新生儿。使用该方案的试点数据(N=10)表明,新生儿学生对阿片类药物的反应与成人相同,并表明瞳孔直径可能是一个更敏感的测量NAS相比,两个额定规模。 因此,下一步是全面测试阿片类药物暴露新生儿瞳孔直径的可靠性和有效性。 两学 旨在实现这一总体目标。第一项研究将在40名阿片类药物暴露的新生儿中正式测试瞳孔摄影方案的可靠性。第二项研究将使用关于阿片类药物瞳孔效应的大量成人文献作为指导,测试新生儿瞳孔变化作为阿片类药物效应指标的有效性。110例阿片类药物暴露新生儿和30例未暴露新生儿将为4项有效性分析提供数据。首先,将检查分娩后前24小时内收集的瞳孔直径测量值,看看它们是否能够区分阿片类药物暴露和非暴露的新生儿,测试判别有效性。第二,在阿片类药物暴露的新生儿中,将检查分娩后前24小时内瞳孔直径变化与新生儿评定的NAS量表评分变化之间的相关性,测试并行有效性。第三,阿片类药物耐受性和 将在需要药物治疗的阿片类药物暴露新生儿(估计n= 35)中检查阿片类药物给药后瞳孔效应的时程,检验结构有效性。第四次也是最后一次分析将通过检测分娩后前24小时内瞳孔直径的变化是否可预测哪些新生儿继续接受药物治疗来检查预测有效性。总之,在阿片类药物暴露的新生儿中建立瞳孔直径的可靠性和有效性,有可能在临床和研究环境中大大改善阿片类药物暴露新生儿的评估和治疗,降低发病率,缩短住院时间,并降低成本。 公共卫生关系:瞳孔大小是衡量阿片类药物(如海洛因和美沙酮)戒断严重程度以及阿片类药物其他影响的最敏感和最常用的指标之一,并且很容易在成人眼睛的照片中测量。据我们所知,瞳孔的大小从来没有被测量过的婴儿退出阿片类药物后,在子宫内暴露。本研究的主要目的是检验阿片类药物暴露婴儿瞳孔大小测量的可靠性和有效性。拟议的研究具有显着的潜力,以改善检测和治疗的戒断症状,在这个特殊的 人口

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sarah H Heil其他文献

Sarah H Heil的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sarah H Heil', 18)}}的其他基金

Medically-supervised withdrawal vs. agonist maintenance in the treatment of pregnant women with opioid use disorder: Maternal, fetal, and neonatal outcomes
治疗患有阿片类药物使用障碍的孕妇的医学监督戒断与激动剂维持治疗:孕产妇、胎儿和新生儿结局
  • 批准号:
    9903275
  • 财政年份:
    2018
  • 资助金额:
    $ 41.81万
  • 项目类别:
Medically-supervised withdrawal vs. agonist maintenance in the treatment of pregnant women with opioid use disorder: Maternal, fetal, and neonatal outcomes
治疗患有阿片类药物使用障碍的孕妇的医学监督戒断与激动剂维持治疗:孕产妇、胎儿和新生儿结局
  • 批准号:
    10375543
  • 财政年份:
    2018
  • 资助金额:
    $ 41.81万
  • 项目类别:
Improving Effective Contraceptive use Among Opioid-Maintained Women: Stage II
改善使用阿片类药物的女性的有效避孕方法:第二阶段
  • 批准号:
    8759161
  • 财政年份:
    2014
  • 资助金额:
    $ 41.81万
  • 项目类别:
Low Nicotine Content Cigarettes in Vulnerable Populations: Pregnant Women
弱势人群中的低尼古丁含量香烟:孕妇
  • 批准号:
    10477410
  • 财政年份:
    2013
  • 资助金额:
    $ 41.81万
  • 项目类别:
Low Nicotine Content Cigarettes in Vulnerable Populations: Pregnant Women
弱势人群中的低尼古丁含量香烟:孕妇
  • 批准号:
    10247030
  • 财政年份:
    2013
  • 资助金额:
    $ 41.81万
  • 项目类别:
Testing the Reliability and Validity of Pupil Diameter in Opioid-exposed neonates
测试阿片类药物暴露新生儿瞳孔直径的可靠性和有效性
  • 批准号:
    8699737
  • 财政年份:
    2012
  • 资助金额:
    $ 41.81万
  • 项目类别:
Testing the Reliability and Validity of Pupil Diameter in Opioid-exposed neonates
测试阿片类药物暴露新生儿瞳孔直径的可靠性和有效性
  • 批准号:
    8545754
  • 财政年份:
    2012
  • 资助金额:
    $ 41.81万
  • 项目类别:
Improving effective contraceptive use among opioid-maintained women
改善使用阿片类药物的女性的有效避孕方法
  • 批准号:
    8309018
  • 财政年份:
    2011
  • 资助金额:
    $ 41.81万
  • 项目类别:
Improving effective contraceptive use among opioid-maintained women
改善使用阿片类药物的女性的有效避孕方法
  • 批准号:
    8190800
  • 财政年份:
    2011
  • 资助金额:
    $ 41.81万
  • 项目类别:
CLINICAL TRIAL: MOTHER
临床试验:母亲
  • 批准号:
    7952101
  • 财政年份:
    2009
  • 资助金额:
    $ 41.81万
  • 项目类别:

相似海外基金

CALIBER: Conductive Additives to reduce Lithium Ion Battery Electrode Resistance
CALIBER:降低锂离子电池电极电阻的导电添加剂
  • 批准号:
    10004505
  • 财政年份:
    2021
  • 资助金额:
    $ 41.81万
  • 项目类别:
    BEIS-Funded Programmes
Functional evaluation of bioabsorbable small-caliber vascular graft in a diabetic rat model to achieve a practical use
生物可吸收小口径血管移植物在糖尿病大鼠模型中的功能评价以实现实用化
  • 批准号:
    21K08812
  • 财政年份:
    2021
  • 资助金额:
    $ 41.81万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Enhanced degradability of bioabsorbable small-caliber artificial vessels to promote autologous vascular regeneration
增强生物可吸收小口径人工血管的降解性促进自体血管再生
  • 批准号:
    21K20938
  • 财政年份:
    2021
  • 资助金额:
    $ 41.81万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Engineering a biomimetic small caliber vascular prosthesis: fabrication of an anti-thrombogenic endothelium from the stromal vascular fraction of adipose tissue
设计仿生小口径血管假体:从脂肪组织的基质血管部分制造抗血栓内皮
  • 批准号:
    518445-2018
  • 财政年份:
    2020
  • 资助金额:
    $ 41.81万
  • 项目类别:
    Postgraduate Scholarships - Doctoral
Morphological and Biochemical Profiling of the Degeneration of Small Caliber Axons Using a Murine Model for Myelin-related Diseases
使用髓磷脂相关疾病的小鼠模型对小口径轴突变性进行形态学和生化分析
  • 批准号:
    20KK0188
  • 财政年份:
    2020
  • 资助金额:
    $ 41.81万
  • 项目类别:
    Fund for the Promotion of Joint International Research (Fostering Joint International Research (B))
Elucidation of the mechanism of small caliber axons' myelination in the central nervous system and its application
中枢神经系统小口径轴突髓鞘化机制的阐明及其应用
  • 批准号:
    20K07756
  • 财政年份:
    2020
  • 资助金额:
    $ 41.81万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
In vitro endothelialization of small caliber vascular prostheses made of bacterial nanocellulose depending on coating with albumin, fibronectin or heparin
由细菌纳米纤维素制成的小口径血管假体的体外内皮化取决于白蛋白、纤连蛋白或肝素的涂层
  • 批准号:
    421965288
  • 财政年份:
    2019
  • 资助金额:
    $ 41.81万
  • 项目类别:
    Research Grants
Engineering a biomimetic small caliber vascular prosthesis: fabrication of an anti-thrombogenic endothelium from the stromal vascular fraction of adipose tissue
设计仿生小口径血管假体:从脂肪组织的基质血管部分制造抗血栓内皮
  • 批准号:
    518445-2018
  • 财政年份:
    2019
  • 资助金额:
    $ 41.81万
  • 项目类别:
    Postgraduate Scholarships - Doctoral
Anti-atherosclerotic action of platelet-derived endothelial cell growth factor to improve patency of small-caliber artificial blood vessels
血小板源性内皮细胞生长因子的抗动脉粥样硬化作用可改善小口径人造血管的通畅性
  • 批准号:
    18K08753
  • 财政年份:
    2018
  • 资助金额:
    $ 41.81万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Engineering a biomimetic small caliber vascular prosthesis: fabrication of an anti-thrombogenic endothelium from the stromal vascular fraction of adipose tissue
设计仿生小口径血管假体:从脂肪组织的基质血管部分制造抗血栓内皮
  • 批准号:
    518445-2018
  • 财政年份:
    2018
  • 资助金额:
    $ 41.81万
  • 项目类别:
    Postgraduate Scholarships - Doctoral
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了